Phare Bio, a biotech social venture harnessing artificial intelligence to accelerate antibiotic discovery and development, and Basilea Pharmaceutica, a commercial-stage biopharmaceutical company ...
Allschwil, Switzerland, December 11, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company ...
The TARGET (Transforming Antibiotic R&D with Generative AI to stop Emerging Threats) Project is enabling Phare Bio to rapidly scale and optimize its generative AI discovery platform to thwart the ...
Phare Bio has been awarded $27 million in funding from the Advanced Research Projects Agency for Health (ARPA-H). The biotech startup will use the money to advance its antibiotic discovery initiative.
MURRAY, Utah, Oct. 22, 2025 (GLOBE NEWSWIRE) -- R1 (“R1” or the “Company”), the leader in healthcare revenue management, today announced the launch of the Phare Operating System, healthcare’s first ...
Delivers on R1’s Long-Term Investments in People and Technology to Transform the Revenue Cycle Through Sustained, AI-Driven Innovation MURRAY, Utah, Oct. 22, 2025 (GLOBE NEWSWIRE) -- R1 ("R1” or the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback